Elekta AB (publ) Competitors

Quest Diagnostics (NYSE:DGX) and Elekta AB (publ) (OTCMKTS:EKTAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Dividends

Quest Diagnostics pays an annual dividend of $2.48 per share and has a dividend yield of 1.9%. Elekta AB (publ) pays an annual dividend of $0.14 per share and has a dividend yield of 1.0%. Quest Diagnostics pays out 37.8% of its earnings in the form of a dividend. Quest Diagnostics has raised its dividend for 1 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Quest Diagnostics and Elekta AB (publ), as provided by MarketBeat.com.

Quest Diagnostics presently has a consensus price target of $128.8750, indicating a potential downside of 0.95%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, equities analysts plainly believe Quest Diagnostics is more favorable than Elekta AB (publ).

Volatility & Risk

Quest Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Quest Diagnostics and Elekta AB (publ)'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Quest Diagnostics and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Quest Diagnostics has higher revenue and earnings than Elekta AB (publ).

Insider and Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Quest Diagnostics beats Elekta AB (publ) on 13 of the 16 factors compared between the two stocks.

Guardant Health (NASDAQ:GH) and Elekta AB (publ) (OTCMKTS:EKTAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Guardant Health and Elekta AB (publ), as provided by MarketBeat.com.

Guardant Health presently has a consensus price target of $170.50, indicating a potential upside of 7.57%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Elekta AB (publ).

Risk & Volatility

Guardant Health has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares Guardant Health and Elekta AB (publ)'s net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Guardant Health and Elekta AB (publ)'s top-line revenue, earnings per share and valuation.

Elekta AB (publ) has higher revenue and earnings than Guardant Health.

Institutional and Insider Ownership

84.9% of Guardant Health shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 13.0% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Elekta AB (publ) beats Guardant Health on 7 of the 13 factors compared between the two stocks.

Natera (NASDAQ:NTRA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Natera and Elekta AB (publ)'s net margins, return on equity and return on assets.

Risk & Volatility

Natera has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Institutional and Insider Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Natera and Elekta AB (publ)'s top-line revenue, earnings per share and valuation.

Elekta AB (publ) has higher revenue and earnings than Natera.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Natera and Elekta AB (publ), as provided by MarketBeat.com.

Natera presently has a consensus price target of $113.70, indicating a potential upside of 6.31%. Given Natera's stronger consensus rating and higher probable upside, equities analysts plainly believe Natera is more favorable than Elekta AB (publ).

Summary

Natera beats Elekta AB (publ) on 7 of the 13 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Invitae and Elekta AB (publ)'s net margins, return on equity and return on assets.

Volatility and Risk

Invitae has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

78.6% of Invitae shares are held by institutional investors. Comparatively, 0.0% of Elekta AB (publ) shares are held by institutional investors. 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Invitae and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Elekta AB (publ) has higher revenue and earnings than Invitae.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Invitae and Elekta AB (publ), as reported by MarketBeat.

Invitae presently has a consensus target price of $49.3333, indicating a potential upside of 31.07%. Given Invitae's stronger consensus rating and higher possible upside, research analysts plainly believe Invitae is more favorable than Elekta AB (publ).

Summary

Invitae beats Elekta AB (publ) on 7 of the 13 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares CareDx and Elekta AB (publ)'s net margins, return on equity and return on assets.

Volatility and Risk

CareDx has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Elekta AB (publ) shares are held by institutional investors. 3.1% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares CareDx and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Elekta AB (publ) has higher revenue and earnings than CareDx.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CareDx and Elekta AB (publ), as reported by MarketBeat.

CareDx presently has a consensus target price of $75.8333, indicating a potential upside of 2.10%. Given CareDx's stronger consensus rating and higher possible upside, research analysts plainly believe CareDx is more favorable than Elekta AB (publ).

Summary

Elekta AB (publ) beats CareDx on 8 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Elekta AB (publ) (OTCMKTS:EKTAY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

0.0% of Elekta AB (publ) shares are held by institutional investors. 8.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Veracyte and Elekta AB (publ)'s top-line revenue, earnings per share (EPS) and valuation.

Elekta AB (publ) has higher revenue and earnings than Veracyte.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Veracyte and Elekta AB (publ), as reported by MarketBeat.

Veracyte presently has a consensus target price of $66.1429, indicating a potential upside of 37.31%. Given Veracyte's stronger consensus rating and higher possible upside, research analysts plainly believe Veracyte is more favorable than Elekta AB (publ).

Profitability

This table compares Veracyte and Elekta AB (publ)'s net margins, return on equity and return on assets.

Volatility and Risk

Veracyte has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Elekta AB (publ) has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Summary

Elekta AB (publ) beats Veracyte on 8 of the 13 factors compared between the two stocks.